Back to Find a Doctor
David R. Goldsmith

David R. Goldsmith, MD

Co-Director; Persistent Symptoms: Treatment, Assessment, Recover (PSTAR) Clinic

David Goldsmith is a board-certified psychiatrist who focuses on the treatment of psychotic disorders and studies the role of the immune system in persistent symptoms of schizophrenia. More specifically, he is interested in how inflammation targets the brain, leading to motivational deficits and negative symptoms of schizophrenia. He is the co-director of the PSTAR (Persistent Symptoms: Treatment, Assessment, and Recovery) Clinic at Grady Memorial Hospital, which focuses on the treatment of individuals with psychosis, with a specific emphasis on using clozapine and other pharmacologic/psychosocial interventions for persistent symptoms. In addition to his work in the PSTAR Clinic, Dr. Goldsmith is on the faculty of the Emory Behavioral Immunology Program and is the Associate Program Director for the Emory Psychiatry Residency Research Track. Dr. Goldsmith completed his undergraduate work at the University of Maryland and received two National Institute of Mental Health Training Awards before receiving his MD from the Emory University School of Medicine. Dr. Goldsmith completed his psychiatry residency training at Emory University School of Medicine where he was on the residency research track.

Specialties

  • Psychiatry

Board Certifications

  • ABMS Psychiatry/Neurology

Affiliations

  • Emory

Education & Training

  • Medical School: Emory University School of Medicine
  • Residency: Emory University School of Medicine

Honors & Awards

Georgia Clinical and Translational Science Institute KL2 Scholar

National Institute of Health Loan Repayment Program Awardee 2017

Emory School of Medicine Educator Appreciation Day 2017, Faculty Nominee

Department of Psychiatry and Behavioral Sciences PGY1 Faculty Teaching Award, 2017

Publications

Goldsmith DR, Rapaport MH, Miller BJ. Meta-analysis of cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Molecular Psychiatry 2016 Dec;21(12): 1696-1709.

Goldsmith DR, Haroon, E, Woolwine BJ, Jung MY, Wommack EC, Harvey PD, Treadway MT, Felger JC, Miller, AH. Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. Brain Behavior and Immunity 2016. Aug; 56: 281-288.

Miller BJ, Goldsmith DR, Paletta N, Wong J, Kandhal P, Black C, Rapaport MH, Buckley PF. Parental DM2 in patients with nonaffective psychosis. Schizophrenia Research 2016. Aug; 175(1-3)223-225.

Miller BJ, Goldsmith DR. Towards a Schizophrenia Immunophenotype: Progress, Potential Mechanisms, and Future Directions. Neuropsychopharmacology 2017. Jan;42(1):299-317.

Goldsmith DR, Cotes RO. An unmet need: a clozapine-induced myocarditis screening protocol. The Primary Care Companion for CNS Disorders. 2017. Aug 3;19(4).

Complete Bibliography of Published Work: https://www.ncbi.nlm.nih.gov/sites/myncbi/1viQpeawtsAQJ/bibliography/40391497/public/?sort=date&direction =ascending